Search Results for: Omicron

May 11, 2025May 11, 2025

Identifying Neurological Autoantibodies in COVID-19: mGluR2 as a Marker of Immune Dysregulation During the Omicron Outbreak in China.

Publication date: May 01, 2025 Aimed to comprehensively investigate the presence of neural autoantibodies in the cerebrospinal fluid (CSF) and plasma of COVID-19 patients experiencing neurological complications during the Omicron ... Read more

May 10, 2025

Clinical Manifestations of SARS-CoV-2 Infection in Immunocompetent Adults in the Era of Widespread Population Immunity and Omicron Sublineage Viruses.

Coronavirus Literature

Publication date: Jun 01, 2025 While most SARS-CoV-2 infections and reinfections in the era of widespread population immunity with omicron subsub-lineage variants are mild for immunocompetent individuals, any manifestation previously ... Read more

May 10, 2025May 10, 2025

In-hospital Mortality Among Children and Adults Hospitalized with COVID-19 in Africa Across Pre-Delta, Delta, and Omicron SARS-CoV-2 Waves.

Tuberculosis Literature

Publication date: May 07, 2025 This study examines in-hospital mortality among children and adults hospitalized with COVID-19 across the pre-Delta, Delta, and Omicron waves in the African region. We conducted ... Read more

May 9, 2025

Immune Response Against Recent Omicron Sub-Lineages in Persons with HIV Receiving a Protein-Based or mRNA XBB.1.5 SARS-CoV-2 Booster Vaccine.

Coronavirus Literature

Publication date: Apr 09, 2025 The new Nuvaxovid protein-based and Pfizer-BioNTech mRNA-based vaccines targeting Omicron XBB. 1.5 were available during the 2023-2024 autumn/winter vaccination campaign for frail individuals, including people ... Read more

May 9, 2025

Immune Modulation and Efficacy of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Lung Transplant Recipients During the Omicron Wave.

Coronavirus Literature

Publication date: Apr 14, 2025 Lung transplant recipients are at increased risk of severe COVID-19 due to lifelong immunosuppressive therapy, which impairs both innate and adaptive immune responses. Identifying effective ... Read more

May 9, 2025May 9, 2025

Structural and Energetic Insights into SARS-CoV-2 Evolution: Analysis of hACE2-RBD Binding in Wild-Type, Delta, and Omicron Subvariants.

Coronavirus Literature

Publication date: Apr 17, 2025 The evolution of SARS-CoV-2, particularly the emergence of Omicron variants, has raised questions regarding changes in its binding affinity to the human angiotensin-converting enzyme 2 ... Read more

May 2, 2025

A distinctive IGHV3-66 SARS-CoV-2 neutralizing antibody elicited by primary infection with an Omicron variant.

Coronavirus Literature

Publication date: Apr 23, 2025 SARS-CoV-2 Omicron sub-variants continuously evolve under the pressure of neutralizing antibodies (nAbs), eliminating numerous potential elite monoclonal nAbs. The IGHV3-53/3-66 public nAbs have great potential ... Read more

May 2, 2025May 2, 2025

An urgent call to publish COVID-19 trials: a systematic search revealed ZERO studies regarding the incidence of thromboembolic events in SARS-CoV-2 Omicron-infected COVID-19 patients.

Coronavirus Literature

Publication date: May 01, 2025 COVID-19 has been associated with an increased risk of thromboembolic complications, particularly in hospitalized patients. While early research focused on pre-Omicron variants, the thrombotic risk ... Read more

May 1, 2025May 1, 2025

Persistent IP-10/CXCL10 dysregulation following mild omicron breakthrough infection: Immune network signatures across COVID-19 waves and implications for mRNA vaccine outcomes.

Coronavirus Literature

Publication date: Apr 28, 2025 This study explores immune responses in mild Omicron-era COVID-19 breakthrough cases, focusing on cytokine dysregulation, antibody dynamics, and Long COVID. Samples from 114 mild COVID-19 ... Read more

May 1, 2025

Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.

Coronavirus Literature

Publication date: Dec 01, 2025 SARS-CoV-2 vaccination campaigns on current endemic situation would benefit from vaccine alternatives with easy logistics and accessibility, sustained response and cross-reactivity against emerging variants. Herein, ... Read more